Abstract
Importance Risk to airflow limitation and Chronic Obstructive Pulmonary Disease (COPD) is influenced by combinations of cigarette smoking and genetic susceptibility, yet it remains unclear whether gene-by-smoking interactions contribute to quantitative measures of lung function.
Objective Determine whether smoking modifies the effect of a polygenic risk score’s (PRS’s) association with reduced lung function.
Design United Kingdom (UK) Biobank prospective cohort study.
Setting Population cohort.
Participants UK citizens of European ancestry aged 40-69 years, with genetic and spirometry data passing quality control metrics.
Exposures PRS, self-reported pack-years of smoking, ever-versus never-smoking status, and current-versus former-/never-smoking status.
Main Outcomes and Measures Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC). We tested for interactions with models including the main effects of PRS, different smoking variables, and their cross-product term(s). We also compared the effects of pack-years of smoking on FEV1/FVC for those in the highest versus lowest decile of predicted genetic risk for low lung function.
Results We included 319,730 individuals (24,915 with moderate-to-severe COPD). The PRS and pack-years were significantly associated with lower FEV1/FVC, as was the interaction term (β [interaction] = −0.0028 [95% CI: −0.0029, −0.0026]; all p < 0.0001). A stepwise increment in estimated effect sizes for these interaction terms was observed per 10 pack-years of smoking exposure (all p < 0.0001). There was evidence of significant interaction between PRS with ever/never smoking status (β [interaction] = −0.0064 [95% CI: −0.0068, −0.0060]) and current/not-current smoking (β [interaction] = −0.0091 [95% CI: −0.0097, −0.0084]). For any given level of pack-years of smoking exposure, FEV1/FVC was significantly lower for individuals in the tenth compared to the first decile of genetic risk (p < 0.0001). For every 20 pack-years of smoking, those in the top compared to the bottom decile of genetic risk showed nearly a twofold reduction in FEV1/FVC.
Conclusions and Relevance COPD is characterized by diminished lung function, and our analyses suggest there is substantial interaction between genome-wide PRS and smoking exposures. While smoking has negative effects on lung function across all genetic risk categories, effects of smoking are highest in those with higher predicted genetic risk.
Question Does cigarette smoking modify the magnitude of genetic effects on forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC)?
Findings FEV1/FVC is influenced by PRS-by-smoking interactions. Smoking was detrimental across all categories of predicted genetic risk, though it was worse for those with highest predicted genetic risks. For every reported 20 pack-years of reported smoking, individuals in the top compared to the bottom decile of genetic risk showed nearly twice the reduction in FEV1/FVC.
Meaning Elucidating mechanisms for the interaction between smoking and genetic risk could yield greater insight into the pathogenesis of chronic obstructive pulmonary disease (COPD).
Competing Interest Statement
EKS received grant support from GlaxoSmithKline and Bayer. MHC has received grant support from GlaxoSmithKline and Bayer, consulting fees from Genentech and AstraZeneca, and speaking fees from Illumina. MDT receives grant support from GlaxoSmithKline and Orion. LVW received grant support from GlaxoSmithKline and Orion. The other authors report no disclosures.
Funding Statement
MM is supported by T32HL007427. DQ is supported by NIH K01HL129039 and the NHLBI BioData Catalyst Fellow Program. BDH is supported by NIH K08HL136928 and U01 HL089856. MHC is supported by NIH R01HL137927 and R01HL135142. EKS is supported by NIH R01 HL137927, R01 HL147148, U01 HL089856, R01 HL133135, and P01 HL114501 M.D.T. is supported by a Wellcome Trust Investigator Award (WT202849/Z/16/Z). The research was partially supported by the NIHR Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. LVW holds a GSK / British Lung Foundation Chair in Respiratory Research (C17-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants of UK Biobank provided written informed consent and study protocols were approved by the North West Multi-centre Research Ethics Committee. The current study is approved by the UK Biobank under application number 20915.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Co-senior authors
Data Availability
None.
